Clinical Trials Logo
  1. Home
  2. Lung Cancer
  3. NCT04228237
  4. Details
NCT04228237 Clinical Trial

LUng CAncer focuS - Long-term Monitoring of Bronchogenic Carcinoma Patients (LUCAS)

Lung Cancer Clinical Trial

— LUCAS  

Official title:
LUng CAncer focuS - Long Term Non-interventional Monitoring of Diagnostic and Treatment Patterns in Patients With Bronchogenic Carcinoma (LUCAS)

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04228237
Other study ID # CPFS/Reg18.01
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 1, 2018
Est. completion date May 31, 2025

Study information
Verified date March 2022
Source Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s.
Contact Jana Alahakoon
Phone +420602350988
Email jana.alahakoon@oaks.cz
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Long-term non-interventional monitoring of diagnostics and treatment patterns in newly diagnosed patients in selected pneumology centers in Czech republic.

Description:

Diagnosis, treatment and care of patients with bronchogenic carcinoma (BCA) is, as with most other oncological diseases, a complex multidisciplinary process. Due to the lack of information on the speed and success of the initial diagnosis, the use of the necessary laboratory techniques, and the individual therapeutic steps leading to cure or medical failure, the Czech Pneumological and Phtizeology Society (CPPS) decided to carry out long-term non-interventional monitoring of newly diagnosed patients. This monitoring is non-interventional, so the usual diagnostic and therapeutic procedures will be used according to the decision of the physician. All patients with bronchogenic carcinoma diagnosed from June 1, 2018 will be enrolled with up to 60 months of follow-up.

Recruitment information / eligibility
Status Recruiting
Enrollment 2300
Est. completion date May 31, 2025
Est. primary completion date May 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - clinical diagnosis of lung cancer (C34 in MKN classification) Exclusion Criteria:

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Czechia University hospital Brno Brno
Czechia University hospital Hradec Kralove Hradec Kralove
Czechia University hospital Olomouc Olomouc
Czechia University hospital Plzen Plzen
Czechia University Thomayer hospital Prague
Czechia University hospital Motol Praha 5
Czechia University hospital Bulovka Praha 8 Ceská Republika

Sponsors (2)
Lead Sponsor Collaborator
Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s. OAKS Consulting s.r.o.

Country where clinical trial is conducted

Czechia, 

Outcome
Type Measure Description Time frame Safety issue
Primary Overall survival (OS) Time from randomization until death from any cause 60 months of follow-up
Primary Progression-free survival (PFS) Time from randomization until disease progression or death any treatment during 60 months of follow-up
Primary Time to treatment discontinuation (TTD) time from starting a medication until treatment discontinuation or death any treatment during 60 months of follow-up
Secondary Time to next treatment (TTNT) Time from end of primary treatment to institution of next therapy 60 months of follow-up
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk